
Every Cure is a nonprofit initiative focused on unlocking the full potential of existing medicines to treat every disease and patient possible. They employ an AI-driven approach to systematically analyze biomedical knowledge, identifying and advancing drug repurposing opportunities. This method significantly reduces the cost and time typically associated with drug development, aiming to treat diseases for which no cures currently exist. The organization was founded by Dr. David Fajgenbaum, who successfully used a repurposed drug to treat his own life-threatening condition, Castleman disease. Every Cure collaborates with partners in medicine, pharma, tech, and philanthropy to build a comprehensive, open-source database of drug-repurposing opportunities, acting as a central connector in the ecosystem to foster collaboration and deliver life-saving therapies.

Every Cure is a nonprofit initiative focused on unlocking the full potential of existing medicines to treat every disease and patient possible. They employ an AI-driven approach to systematically analyze biomedical knowledge, identifying and advancing drug repurposing opportunities. This method significantly reduces the cost and time typically associated with drug development, aiming to treat diseases for which no cures currently exist. The organization was founded by Dr. David Fajgenbaum, who successfully used a repurposed drug to treat his own life-threatening condition, Castleman disease. Every Cure collaborates with partners in medicine, pharma, tech, and philanthropy to build a comprehensive, open-source database of drug-repurposing opportunities, acting as a central connector in the ecosystem to foster collaboration and deliver life-saving therapies.
Organization type: Nonprofit focused on AI-driven drug repurposing
Founded: 2022
Headquarters: New York, NY, United States
Notable funders: The Audacious Project; ARPA-H
Employee count: 47
Drug development and therapeutics — identifying repurposing opportunities to treat diseases without effective therapies.
2022
Biotechnology / Health nonprofit
60000000.00
Five-year $60M commitment announced Oct 9, 2024
48000000.00
Multi-year contract reported at roughly $48M
“Major philanthropic and federal support (The Audacious Project; ARPA-H) indicating large-scale grant and contract backing”